You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Age-dependent Single-cell Metabolomic and Proteomic Profiling of Human Immune System

    SBC: ISOPLEXIS CORPORATION            Topic: NIA

    With this phase I submissionIsoPlexis proposes to deliver comprehensive profiling of the immune system as a measure of age dependent health in response to medical challenges or traumaThis assay will connect signaling events in the metabolome and proteome from thousands of single cells in parallel enabling the simultaneous tracking of metabolic activity and protein signaling within each immune cell ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Noninvasive biomarkers for gastrointestinal disease in preterm infants

    SBC: CHOSEN DIAGNOSTICS INC            Topic: NICHD

    The goal and significance of this project is to develop a clinically usable diagnostic test for gastrointestinal disease and to reduce healthcare costsNecrotizing enterocolitisNECis the most frequent and lethal gastrointestinal disease for preterm infantsIt affects newborns at a rate ofperUS births per year and has an average total in hospital treatment cost of $per patientAlthough first described ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Nanoentrapped polyphenol coatings for sustained release from angioplasty balloons

    SBC: REQUISITE BIOMEDICAL, LLC            Topic: NHLBI

    PROJECT SUMMARYPeripheral artery diseasePADis a serious cardiovascular disease affectingmillion people worldwidePAD is defined by a blockage of arteries in the lower extremitiesand is associated with painpoor wound healingand without interventionlimb loss and deathDrug coated balloonsDCBare an emerging clinical intervention aimed at clearing blocked arteriesparticularly those that are difficult to ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Repurposing a Pinworm Drug to Treat Pulmonary Fibrosis

    SBC: SegueTX-Pancreatic Cancer, L.L.C.            Topic: NHLBI

    PROJECT SUMMARY Pulmonary fibrosis is a leading cause of death worldwide. With a median survival of only 2.5 years after diagnosis, it is responsible for millions of deaths worldwide and billions in health care costs each year. Besides mortality, pulmonary fibrosis, of which the idiopathic type is most common, brings about tragic morbidity. Without a known cause of idiopathic pulmonary fibrosis, v ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Universal Membrane Dehydrator for Dewatering Pharmaceutical Solvents

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: 400

    Project Summary Specific AimThere are numerous needs in the pharmaceutical industry to use and recover high purity solventsKey uses includehigh purity alcohol for various applicationsthe ability to develop low cost dewatering of solvents and a relatively gentle and simple process for dewatering solvent under mild conditionsCompact Membrane SystemsCMSproposes a novel membrane process that can lead ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer’s Disease

    SBC: Oleolive, Inc.            Topic: NIA

    PROJECT SUMMARY Alzheimer’s disease (AD) is the sixth leading cause of death in United States, yet this indication lacks truly effective therapeutics to mitigate this disease. To address this problem, a novel (partial) peroxisomal proliferator activating–gamma (PPAR) nuclear receptor agonist (AU-9) that has selective amino acid interactions in the receptor ligand-binding domain was develope ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Multi-Omic Single-Cell System for Improved Combination Cancer Immunotherapy Monitoring and Implementation

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    IsoPlexis proposes to deliver a novel multi-omic method for targeted profiling of both the TCR sequence and proteome from an array of 1000+ single cells. Specifically, we will deliver a single-cell, TCR sequencing and protein capture assay for identifying responsive antigen specific TCRs, and concurrently evaluate these T-cells for functional response to that antigen. The challenge remains to link ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Although signal transduction inhibitors occasionally offer clinical benefit for cancer patients, signal flux emanating from oncogenes is often distributed through multiple pathways, potentially underlying the resistance which causes failure of most such inhibitors. Measuring signal flux through multiple pathways, in response to signal transduction inhibitors, may help uncover network inter- action ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of mitoNEET agonists for the treatment of stroke

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Stroke is the fifth leading cause of death and the leading cause of disability in the United StatesThere remains a critical need for innovative therapeutic approaches that can successfully prevent or reverse brain injury following strokeDysfunction of the mitochondrial biochemistry following ischemic stroke and reperfusion injury contributes to significant neuronal cell losshoweverthe dev ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government